Figure 4.

pG1 sensitizes resistant BTK^WT MCL cells to ibrutinib [reproduced from reference (21) with permission]. (A) Schema for sequential incubation with PD 0332991 (palbociclib, 0.3 μmol/L) and ibrutinib (left). The total viable cells (×20,000 cells/mL) at 48 and 96 hours of ibrutinib treatment in 4 MCL cell lines (1 μmol/L for JEKO-1, MAVER-1 and MINO and 0.1 μmol/L for SP53) were determined (right). (B) Immunoblotting of activated BTK (pY223) and total BTK, activated AKT (pS473) and total AKT proteins in JEKO-1 cells cultured in the presence or absence of PD 0332991 (0.3 μmol/L) for 24 hours before addition of goat antihuman IgM (α-IgM, 5 μg/mL) to enhance B cell receptor signaling and ibrutinib (1 μmol/L) for 24 hours. pG1, prolonged early G1 arrest; MCL, mantle cell lymphoma.